Coagulation, or blood clotting, is caused by a rapid chain reaction of proteins in your blood that activates in response to damage in a blood vessel wall. The process involves platelets, over a dozen clotting factors, calcium, and vitamin K, all working together to seal a wound and stop bleeding. It happens in two overlapping stages: first, platelets form a temporary plug at the injury site, and then a cascade of protein reactions reinforces that plug with a tough mesh of fibrin.
How a Blood Vessel Injury Starts the Process
Under normal conditions, the cells lining your blood vessels keep clotting factors in an inactive state. Clotting proteins circulate in your blood at all times, but they’re switched off. The trigger is damage to the vessel wall, whether from a cut, a bruise, or internal trauma like a surgical incision.
When a blood vessel is damaged, two things happen almost simultaneously. The vessel constricts to slow blood flow to the area, and the inner lining tears open to expose a layer of collagen and a protein called tissue factor that are normally hidden beneath the surface. These exposed proteins are the signal that launches coagulation. Tissue factor binds to a clotting protein already floating in the blood, forming a complex that kicks off the enzymatic chain reaction. At the same time, collagen and another sticky protein called von Willebrand factor act as anchoring points for platelets rushing to the scene.
Platelets Build the First Plug
Within seconds of an injury, platelets begin sticking to the exposed collagen at the wound site. This is called platelet adhesion, and it depends on von Willebrand factor acting as a molecular bridge between the collagen and receptors on the platelet surface. Once attached, the platelets change shape, extending arm-like projections that help them grip the damaged area and each other.
Attached platelets then release the contents of tiny storage granules inside them. These chemicals, including ADP, serotonin, and a compound called thromboxane A2, do two things: they attract more platelets to the area and activate them. Activated platelets become sticky and begin clumping together in a process called aggregation, forming a soft, temporary seal known as the primary platelet plug. This plug can slow bleeding on its own for small injuries, but it isn’t strong enough to last. It needs reinforcement from the coagulation cascade.
The Coagulation Cascade: Two Paths to One Goal
The cascade is a series of reactions where one clotting factor activates the next, like dominoes falling. It has two entry points, called the intrinsic and extrinsic pathways, that converge into a single common pathway. The end product is always the same: fibrin, a protein that forms a tough, mesh-like net over the platelet plug.
The Extrinsic Pathway
This is the faster route. It starts when tissue factor, released from damaged cells, binds to factor VII in the blood and activates it. The activated factor VII then converts factor X into its active form, factor Xa. This pathway is considered “extrinsic” because tissue factor comes from outside the bloodstream itself.
The Intrinsic Pathway
This pathway is triggered when blood contacts the exposed collagen beneath a damaged vessel lining. Contact with collagen activates factor XII, which then activates factor XI, which activates factor IX. Factor IX, working with factor VIII as a helper, ultimately activates factor X. The intrinsic pathway is slower but amplifies the clotting signal significantly.
The Common Pathway
Both pathways feed into the activation of factor X, which is where the common pathway begins. Activated factor X, with help from factor V, converts prothrombin (factor II) into thrombin. Thrombin is the central enzyme of clotting. It does several things at once: it converts fibrinogen, a soluble protein in your blood, into insoluble fibrin strands. It also activates factor XIII, which cross-links those fibrin strands into a stable mesh. And it loops back to amplify the earlier steps, activating more factor V, factor VIII, and factor XI to accelerate the entire process.
The fibrin mesh weaves through and around the platelet plug, turning a fragile seal into a durable clot that can withstand the pressure of blood flow.
Vitamin K and Calcium Are Essential
Several clotting factors, including prothrombin and factors VII, IX, and X, are manufactured in the liver and require vitamin K to function. Vitamin K enables a chemical modification that allows these proteins to bind calcium ions, and without that calcium-binding ability, they can’t participate in the cascade. This is why vitamin K deficiency causes bleeding problems, and why the blood thinner warfarin works by blocking vitamin K’s activity.
Calcium ions themselves are required at multiple steps in the cascade, particularly in forming the enzyme complexes that activate factor X and convert prothrombin to thrombin. Your body tightly regulates blood calcium levels, so dietary calcium deficiency rarely causes clotting problems directly. But in a lab setting, removing calcium from a blood sample will prevent it from clotting entirely, which is how blood banks keep donated blood liquid.
What Keeps Clotting From Spreading Too Far
A clot that grows beyond the injury site can block a blood vessel, so your body has built-in brakes. The most important is antithrombin, a protein that directly inactivates thrombin and factor Xa. Its effect is amplified roughly 100-fold by heparin, a natural molecule found on the surface of blood vessel cells (and the basis for heparin medications used in hospitals).
Another braking system is the protein C pathway. When thrombin binds to a receptor on intact blood vessel cells nearby, it activates protein C instead of promoting more clotting. Activated protein C, assisted by protein S, shuts down factors V and VIII, effectively turning off the cascade in areas where the vessel wall is healthy. This elegant feedback loop uses thrombin, the same enzyme that drives clotting, to also limit it.
How the Body Dissolves a Clot
Once a vessel has healed, the clot needs to be cleared. Your body handles this through a process called fibrinolysis. A protein called plasminogen binds directly to fibrin strands within the clot. Activating signals then convert plasminogen into plasmin, an enzyme that cuts fibrin into small, soluble fragments that are carried away in the bloodstream. To prevent plasmin from dissolving clots prematurely, a circulating inhibitor called alpha-antiplasmin keeps it in check until the right moment.
What Causes Abnormal Clotting
When the coagulation system malfunctions, it can tip in either direction: too little clotting (bleeding disorders) or too much (clot formation in healthy vessels). Excessive clotting, called hypercoagulability, has both genetic and acquired causes.
The most common genetic risk factor is Factor V Leiden, a mutation that makes factor V resistant to being shut down by activated protein C. Another common inherited cause is the prothrombin gene mutation (G20210A), which leads to higher-than-normal levels of prothrombin in the blood. Both increase the risk of developing blood clots in veins, particularly in the legs.
Acquired causes are more varied. Cancer is one of the most common, as tumors can release tissue factor and other substances that activate clotting. Prolonged immobility, whether from bed rest after surgery, a long flight, or a sedentary hospital stay, slows blood flow enough to promote clot formation. Surgery, trauma, certain medications, and pregnancy also shift the balance toward clotting.
How Clotting Function Is Tested
Two common blood tests measure how well your coagulation system works. The prothrombin time (PT) test evaluates the extrinsic and common pathways. Normal results fall between 11 and 13.5 seconds, often reported as an INR value of 0.8 to 1.1. People taking warfarin typically aim for an INR of 2.0 to 3.0. The partial thromboplastin time (PTT) test evaluates the intrinsic pathway. Together, these tests help identify which part of the cascade may be underperforming or overactive, guiding diagnosis of bleeding disorders, liver disease, or clotting factor deficiencies.
A result that’s too high means blood is clotting too slowly, raising the risk of excessive bleeding. A result that’s too low can signal a tendency toward dangerous clot formation. These tests are also routine before surgeries and for monitoring blood-thinning medications.